A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
Abstract Background South Asians have a high risk to develop type 2 diabetes, which may be related to substantial ectopic fat deposition. Since glucagon-like peptide-1 analogues can reduce ectopic fat accumulation, the aim of the present study was to assess the effect of treatment with liraglutide f...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-07-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12933-019-0890-5 |
| _version_ | 1818491510804447232 |
|---|---|
| author | Huub J. van Eyk Elisabeth H. M. Paiman Maurice B. Bizino Paul de Heer Petronella H. Geelhoed-Duijvestijn Aan V. Kharagjitsingh Johannes W. A. Smit Hildo J. Lamb Patrick C. N. Rensen Ingrid M. Jazet |
| author_facet | Huub J. van Eyk Elisabeth H. M. Paiman Maurice B. Bizino Paul de Heer Petronella H. Geelhoed-Duijvestijn Aan V. Kharagjitsingh Johannes W. A. Smit Hildo J. Lamb Patrick C. N. Rensen Ingrid M. Jazet |
| author_sort | Huub J. van Eyk |
| collection | DOAJ |
| description | Abstract Background South Asians have a high risk to develop type 2 diabetes, which may be related to substantial ectopic fat deposition. Since glucagon-like peptide-1 analogues can reduce ectopic fat accumulation, the aim of the present study was to assess the effect of treatment with liraglutide for 26 weeks on ectopic fat deposition and HbA1c in South Asian patients with type 2 diabetes. Methods In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after 26 weeks of treatment we assessed abdominal subcutaneous, visceral, epicardial and paracardial adipose tissue volume using MRI. Furthermore, myocardial and hepatic triglyceride content were examined with proton magnetic resonance spectroscopy. Results In the intention-to-treat analysis, liraglutide decreased body weight compared to placebo (− 3.9 ± 3.6 kg vs − 0.6 ± 2.2 kg; mean change from baseline (liraglutide vs placebo): − 3.5 kg; 95% CI [− 5.3, − 1.8]) without significant effects on the different adipose tissue compartments. HbA1c was decreased in both groups without between group differences. In the per-protocol analysis, liraglutide did decrease visceral adipose tissue volume compared to placebo (− 23 ± 27 cm2 vs − 2 ± 17 cm2; mean change from baseline (liraglutide vs placebo): − 17 cm2; 95% CI [− 32, − 3]). Furthermore, HbA1c was decreased by liraglutide compared to placebo (− 1.0 ± 0.8% (− 10.5 ± 9.1 mmol/mol)) vs (− 0.6 ± 0.8% (− 6.1 ± 8.8 mmol/mol)), with a between group difference (mean change from baseline (liraglutide vs placebo): − 0.6% (− 6.5 mmol/mol); 95% CI [− 1.1, − 0.1 (− 11.5, − 1.5)]). Interestingly, the decrease of visceral adipose tissue volume was associated with the reduction of HbA1c (β: 0.165 mmol/mol (0.015%) per 1 cm2 decrease of visceral adipose tissue volume; 95% CI [0.062, 0.267 (0.006, 0.024%)]). Conclusions While the intention-to-treat analysis did not show effects of liraglutide on ectopic fat and HbA1c, per-protocol analysis showed that liraglutide decreases visceral adipose tissue volume, which was associated with improved glycaemic control in South Asians. Trial registration NCT02660047 (clinicaltrials.gov). Registered 21 January 2016 |
| first_indexed | 2024-12-10T17:31:59Z |
| format | Article |
| id | doaj.art-8192e95d0a7f403ab3e6c270721e4b7a |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-12-10T17:31:59Z |
| publishDate | 2019-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-8192e95d0a7f403ab3e6c270721e4b7a2022-12-22T01:39:39ZengBMCCardiovascular Diabetology1475-28402019-07-0118111210.1186/s12933-019-0890-5A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patientsHuub J. van Eyk0Elisabeth H. M. Paiman1Maurice B. Bizino2Paul de Heer3Petronella H. Geelhoed-Duijvestijn4Aan V. Kharagjitsingh5Johannes W. A. Smit6Hildo J. Lamb7Patrick C. N. Rensen8Ingrid M. Jazet9Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC)Dept. Radiology, LUMCDept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC)Dept. Radiology and Nuclear Medicine, Amsterdam University Medical CenterDept. Medicine, Haaglanden Medical CenterDept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC)Dept. Medicine, Radboud University Medical CenterDept. Radiology, LUMCDept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC)Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC)Abstract Background South Asians have a high risk to develop type 2 diabetes, which may be related to substantial ectopic fat deposition. Since glucagon-like peptide-1 analogues can reduce ectopic fat accumulation, the aim of the present study was to assess the effect of treatment with liraglutide for 26 weeks on ectopic fat deposition and HbA1c in South Asian patients with type 2 diabetes. Methods In a placebo-controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after 26 weeks of treatment we assessed abdominal subcutaneous, visceral, epicardial and paracardial adipose tissue volume using MRI. Furthermore, myocardial and hepatic triglyceride content were examined with proton magnetic resonance spectroscopy. Results In the intention-to-treat analysis, liraglutide decreased body weight compared to placebo (− 3.9 ± 3.6 kg vs − 0.6 ± 2.2 kg; mean change from baseline (liraglutide vs placebo): − 3.5 kg; 95% CI [− 5.3, − 1.8]) without significant effects on the different adipose tissue compartments. HbA1c was decreased in both groups without between group differences. In the per-protocol analysis, liraglutide did decrease visceral adipose tissue volume compared to placebo (− 23 ± 27 cm2 vs − 2 ± 17 cm2; mean change from baseline (liraglutide vs placebo): − 17 cm2; 95% CI [− 32, − 3]). Furthermore, HbA1c was decreased by liraglutide compared to placebo (− 1.0 ± 0.8% (− 10.5 ± 9.1 mmol/mol)) vs (− 0.6 ± 0.8% (− 6.1 ± 8.8 mmol/mol)), with a between group difference (mean change from baseline (liraglutide vs placebo): − 0.6% (− 6.5 mmol/mol); 95% CI [− 1.1, − 0.1 (− 11.5, − 1.5)]). Interestingly, the decrease of visceral adipose tissue volume was associated with the reduction of HbA1c (β: 0.165 mmol/mol (0.015%) per 1 cm2 decrease of visceral adipose tissue volume; 95% CI [0.062, 0.267 (0.006, 0.024%)]). Conclusions While the intention-to-treat analysis did not show effects of liraglutide on ectopic fat and HbA1c, per-protocol analysis showed that liraglutide decreases visceral adipose tissue volume, which was associated with improved glycaemic control in South Asians. Trial registration NCT02660047 (clinicaltrials.gov). Registered 21 January 2016http://link.springer.com/article/10.1186/s12933-019-0890-5South AsianDiabetes mellitus type 2Ectopic fatGLP-1 analogueLiraglutideRandomised clinical trial |
| spellingShingle | Huub J. van Eyk Elisabeth H. M. Paiman Maurice B. Bizino Paul de Heer Petronella H. Geelhoed-Duijvestijn Aan V. Kharagjitsingh Johannes W. A. Smit Hildo J. Lamb Patrick C. N. Rensen Ingrid M. Jazet A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients Cardiovascular Diabetology South Asian Diabetes mellitus type 2 Ectopic fat GLP-1 analogue Liraglutide Randomised clinical trial |
| title | A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients |
| title_full | A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients |
| title_fullStr | A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients |
| title_full_unstemmed | A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients |
| title_short | A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients |
| title_sort | double blind placebo controlled randomised trial to assess the effect of liraglutide on ectopic fat accumulation in south asian type 2 diabetes patients |
| topic | South Asian Diabetes mellitus type 2 Ectopic fat GLP-1 analogue Liraglutide Randomised clinical trial |
| url | http://link.springer.com/article/10.1186/s12933-019-0890-5 |
| work_keys_str_mv | AT huubjvaneyk adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT elisabethhmpaiman adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT mauricebbizino adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT pauldeheer adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT petronellahgeelhoedduijvestijn adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT aanvkharagjitsingh adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT johanneswasmit adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT hildojlamb adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT patrickcnrensen adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT ingridmjazet adoubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT huubjvaneyk doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT elisabethhmpaiman doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT mauricebbizino doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT pauldeheer doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT petronellahgeelhoedduijvestijn doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT aanvkharagjitsingh doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT johanneswasmit doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT hildojlamb doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT patrickcnrensen doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients AT ingridmjazet doubleblindplacebocontrolledrandomisedtrialtoassesstheeffectofliraglutideonectopicfataccumulationinsouthasiantype2diabetespatients |